FDA approved a record number of novel treatments in 2018.
FDA approved a record number of novel treatments in 2018.
FDA’s Center for Drug Evaluation and Research (CDER) cleared 59 novel drugs, compared to 33 annually on average from 2009 through 2017.
“The decisions we made on these approvals were generally completed by or before their goal dates as defined by Congressionally-approved agreements with industry,” wrote Janet Woodcock, MD, director of CDER, in a new report.
Related: FDA approves first cannabis-based drug for rare forms of epilepsy
Most of the drugs are approved in the US before any other country, Woodcock added.
Thirty-two percent of the novel drugs approved in 2018 were first-in-class-one indicator of the drug’s potential for strong positive impact on the health of the American people, according to the report.
First-in-class approvals included: erenumab-aooe (Aimovig, Amgen and Novartis) to treat migraines, cannabidiol (Epidiolex, GW Pharmaceuticals) to treat seizures in two rare and severe forms of epilepsy, and lofexidine hydrochloride (Lucemyra, US WorldMeds and Salix), the first non-opioid drug approved to help reduce opioid withdrawal symptoms.
Related: New migraine treatments offer options for patients
Plus, many novel drugs were approved for the first time in the US, including fremanezumab–vfrm (Ajovy, Teva) and galcanezumab-gnlm (Emgality, Eli Lilly and Co.) to prevent migraine.
Duvelisib (Copiktra, Verastem Oncology) was cleared to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Segesterone acetate and ethinyl estradiol (Annovera, Therapeutics MD), a combined hormonal contraceptive, is the first vaginal ring contraceptive that can be used for an entire year.
Read more: FDA approves first biosimilar to Rituxan
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 31st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 31st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 31st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More